8-K/A: Biodesix Exceeds 2025 Revenue Guidance, Achieves Q4 Adjusted EBITDA Positivity

Biodesix, Inc. announced preliminary unaudited financial results for Q4 and full-year 2025, reporting strong revenue growth and affirming Adjusted EBITDA positivity for Q4.

Summary

• Total revenue for the fourth quarter of 2025 is estimated at $28.8 million, marking a 41% increase over the prior year comparable period.
• Full-year 2025 total revenue is estimated at $88.5 million, an increase of 24% over the prior year, exceeding the company's increased guidance of $84-$86 million.
• Lung Diagnostics revenue for Q4 2025 is estimated at $25.2 million (up 47%) and for full-year 2025 at $79.2 million (up 22%).
• Lung Diagnostics test volumes reached 18,000 in Q4 2025 (up 23%) and 62,600 for full-year 2025 (up 15%).
• Development Services revenue is estimated at $3.6 million for Q4 2025 (up 13%) and $9.3 million for full-year 2025 (up 41%).
• The company affirmed its expectation of positive Adjusted EBITDA for the fourth quarter of 2025.
• Cash and cash equivalents stood at $19.0 million as of December 31, 2025, a 14% increase over the third quarter of 2025, including $2.3 million from at-the-market proceeds.

Sentiment

Score: 9

Explanation: The filing reports exceptionally strong preliminary financial results, with full-year revenue significantly exceeding increased guidance and the affirmation of positive Adjusted EBITDA for Q4. This indicates strong operational performance, market penetration, and a positive trajectory towards profitability, reflecting a highly favorable sentiment.

Positives

• Full-year 2025 estimated revenue of $88.5 million exceeded the top end of the increased guidance of $84-$86 million.
• Total revenue increased by 41% in Q4 2025 and 24% for the full year 2025 compared to prior year periods.
• Lung Diagnostics revenue showed significant growth, increasing by 47% in Q4 2025 and 22% for the full year 2025.
• Core organic growth in Lung Diagnostics revenue (excluding claims older than one year) was 41% over the prior year comparable period.
• Development Services revenue grew by 13% in Q4 2025 and 41% for the full year 2025.
• The company affirmed its expectation of achieving positive Adjusted EBITDA in the fourth quarter of 2025.
• Cash and cash equivalents increased to $19.0 million by December 31, 2025, a 14% increase over Q3 2025, demonstrating improved liquidity.

Risks

• Forward-looking statements involve substantial risks and uncertainties, and actual results and performance could differ materially from projections.
• Factors that could cause actual results to differ materially are detailed in the Risk Factors section of the company's most recent Annual Report on Form 10-K (filed March 3, 2025) or subsequent quarterly reports on Form 10-Q.

Future Outlook

The company affirmed its expectation of achieving positive Adjusted EBITDA in the fourth quarter of 2025 and looks forward to building on its momentum in 2026.

Management Comments

• "Biodesix finished 2025 with a strong fourth quarter delivering full year estimated revenue of $88.5 million, exceeding the top end of our increased guidance of $84-$86 million."
• "Throughout the year, we delivered accelerating growth in our Lung Diagnostics testing revenue, driven by an increase in test volumes and continued expansion of reimbursement."
• "We also grew our Development Services revenue while advancing key partnerships."
• "Based on our strong revenue flow-through and operating leverage, we are affirming our expectation of positive Adjusted EBITDA in the fourth quarter."
• "I am exceptionally proud of the Biodesix teams accomplishments in 2025 and their unwavering commitment to the healthcare professionals and the patients we serve. I look forward to building on this momentum in 2026."

Industry Context

Biodesix operates as a leading diagnostic solutions company focused on improving clinical care and outcomes for patients, particularly in lung disease. The reported accelerating growth in Lung Diagnostics testing revenue, driven by increased test volumes and expanded reimbursement, suggests a robust demand for specialized diagnostic tests. The growth in Development Services revenue also indicates successful engagement with biopharmaceutical, life sciences, and research institutions, aligning with broader industry trends of partnerships for diagnostic and therapeutic development.

Stakeholder Impact

• Shareholders: Positive financial results, exceeding guidance, and achieving profitability milestones are likely to enhance shareholder value and confidence.
• Patients: Continued growth in Lung Diagnostics testing revenue and volumes suggests improved access to diagnostic solutions, potentially leading to better clinical care and outcomes.
• Healthcare Professionals: The availability and expansion of Biodesix's diagnostic tests (Nodify Lung, IQLung) support clinical decisions for personalized patient care.
• Biopharmaceutical, Life Sciences, and Research Institutions: Growth in Development Services revenue indicates successful partnerships, enabling the development of diagnostic tests, tools, and therapeutics.

Next Steps

• Building on the momentum achieved in 2025 into 2026.
• Final review and adjustment of preliminary financial results by Biodesix's normal quarter and year-end accounting procedures and external audit.

Key Dates

Recommendation

Biodesix's preliminary Q4 and full-year 2025 results demonstrate exceptional performance, with revenue significantly surpassing increased guidance and the company affirming positive Adjusted EBITDA for Q4. This indicates strong operational execution, accelerating growth in its core Lung Diagnostics segment, and effective cost management leading to a critical profitability milestone. The improved cash position further strengthens the company's financial health. These factors collectively present a compelling investment case, suggesting a strong positive outlook and potential for continued growth.

Keywords

Biodesix, BDSX, financial results, revenue, EBITDA, lung diagnostics, development services, Q4 2025, full-year 2025, preliminary results